Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1995-07-10
2000-12-26
Bansal, Geetha P.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
4353201, 424 931, 424 933, 424 936, 4242771, 4242041, 4242321, A01N 6300, C12N 1563, A61K 3512, A61K 4800
Patent
active
061654604
ABSTRACT:
We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cellular immune response to PSA can be generated. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate the immune response, and contacting the host with additional PSA at periodic intervals thereafter. The additional PSA may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional PSA can be added by contacting the host with PSA by a variety of other methods, including in one preferred embodiment adding PSA. The PSA may be formulated with an adjuvant or in a liposomal formulation.
REFERENCES:
Abulafia R, et al., In-vitro production of T-cells immunoreactive against prostate specific antigen, a movel approach for an antigen-specific adoptive immunotherapy program for prostate cancer. Fed Am Soc Exp Biol J4(7) (1990).
Corman, J.M., et al. Prostate specific antigenic peptides induce T-cell proliferation in-vitro: A model for the development of prostate specific tumor vaccines. Journal of Urology 155 (5 Suppl.) (1996).
Correlae P, et al. Generation of human T-cell lines specific for prostate specific antigen using an oligo-epitope peptide. Proceedings of the American ASsociation for Cancer Research Annual Meeting 37 (0):488-489 (1996).
Hodge, J.W., et al. A recombinant vaccinia virus expressing human prostate--specific antigen (PSA): Safety and immunogenicity in a non-human primate. International Journal of Cancer 63(2):231-237 (1995).
Lu, Edward W., et al. Factors affecting production of antibodies to prostate antigens by in vitro-primed human splenocytes. Hybridoma 12(4):381-9 (1993).
Ross, S., et al. Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex-vivo activated autologous T-cells (autolymphocyte therapy) Results from a pilot study. Biotechnology Therapuetics 4(3-4):197-211 (1993).
Armbruster, D. A. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clinical Chemistry, 39:181-195, (1993).
Bilhartz, D. L., Tindall, D. J., and Oesterling, J. E. Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiological characteristics. Urology, 38:95-102, (1991).
Brawer, M. K., and Lange, P. H. Prostate-specific antigen and premalignant change: implications for early detection. CA Cancer Journal Clinic, 39:361-375, (1989).
Carter, H. B., and Coffey, D. S. The prostate: an increasing medical problem. Prostate, 16:39-48, (1990).
Choe, B. K., Frost, P., Morrison, M. K., and Rose, N R. Natural killer cell activity of prostatic cancer patients. Cancer Investigations, 5:285-291, (1987).
Correale, P., Zaremba, S., Nieroda, C., Zhu, M. Z., Schmitz, J., Schlom, J., and Tsang, K. Y. In vitro stimulation of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen. 9th International Congress of Immunology (Abstract), (1995).
Gauthier, E. R., Chapadelaine, P., Tremblay, R. R., and Dube, J. Y. Characterization of rhesus monkey prostate specific antigen cDNA. Biochimica Biophysica Acta, 1174:207-210, (1993).
Huang, C, L., Brassil, D., Rozzell, M., Schellhammer, P. F., and Wright, G. L. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate, 23:201-212, (1993).
Irvine, K., Kantor, J., and Schlom, J. Comparison of a CEA-recombinant vaccinia virus, purified CEA, and an anti-idiotype antibody bearing the image of a CEA epitope in the treatment and prevention of CEA-expressing tumors. Vaccine Research, 2:79-94, (1993).
Kantor, J., Irvine, K., Abrams, S., Kaufman, H., Dipietro, J., and Schlom, J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. Journal of the National Cancer Institute, 84:1084-1091, (1992a).
Kantor, J., Irvine, K., Abrams, S., Snoy, P., Olsen, R., Greiner, J., Kaufman, H., Eggensperger, D., and Schlom, J. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Research, 52:6917-6925, (1992b).
Karr, J. F., Kantor, J. A., Hand, P. H., Eggensperger, D. L., and Schlom, J. Conservation pf the prostate specific antigen (PSA) gene in primates and the expression of recombinant human PSA in a transfected murine cell line. Cancer Research:Submitted for Publication, (1995).
Kaufman, H., Schlom, J., and Kantor, J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). International Journal of Cancer, 48:900-907, (1991).
Kleer, E., and Oesterling, J. E. PSA and staging of localized prostate cancer. Urologic Clinics of North America, 20:695-704, (1993).
Lundwall, A., and Lilja, H. Molecular cloning of human prostate specific antigen cDNA. FEBS Letters, 214:317-322, (1987).
McEntee, M., Isaacs, W., and Smith, C. Adenocarcinoma of the canine prostate: immunohistochemical examination for secretory antigens. Prostate, 11:163-170, (1987).
Moss, B. Generation of recombinant vaccinia viruses. Current Protocols in Molecular Biology, 2:16.15.1-16.18.9, (1993).
Oesterling, J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. Journal of Urology, 145:907-923, (1991).
Paoletti, E., Tartaglia, J., and Cox, W. I. Immunotherapeutic stratagies for cancer using poxvirus vectors. Annals of the New York Academy of Sciences, 690:292-300, (1993).
Peace, D. J., Xue, B., Sosman, J. A., and Zhang, Y. In vitro immunization of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen. Cancer Vaccines: Structural Basis for Vaccine Development (Abstract), (1994).
Schellhammer, P. F., and Wright, G. L. Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urologic Clinics of North America, 20:597-606, (1993).
Schroder, F. H. Experimental Models in the study of prostate cancer. Prostate Cancer. In: International Perspectives in Urology., 3:343-377, (1982).
Wakui, S., Furusato, M., Nomura, Y., Asari, M., and Kano, Y. Lectin histochemical study of the prostate gland of the rhesus monkey (Macaca mulatta). Journal of Anatomy, 181:127-131, (1992).
Wang, M. C., Kuriyama, M., Papsidero, L. D., Loor, R. M., Valenzuela, L. A., Murphy, G. P., and Chu, T. M. Prostate antigen of human cancer patients. Methods in Cancer Research, 19:179-197, (1982).
Wang, M. C., Valenzuela, L. A., Murphy, G. P., and Chu, T. M. Purification of a human prostate specific antigen. Investigations in Urology, 17:159-163, (1979).
Zietman, A. L., Shipley, W. L., and Willett, C. G. Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer, 71:959-969, (1993).
Donovan, J. F., Lubaroff, D. M., and Williams, R. D. Immunotherapy of prostate cancer. Problems in Urology, 4:489-505, (1990).
Lilja, H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World Journal of Urology, 11:188-191, (1993).
Johnson et al J Virology vol. 68/5; pp. 3145-3153, 1994.
Montefiore et al J. Clin. Immunology 12/6 pp. 429-439, Nov. 1992.
Graham et al J. Infectious Diseases vol. 166/2 p. 244-52, Aug. 1992.
Cooney et al Lancet vol. 337/8741. pp. 567-572, Mar. 9, 1991.
Panicali Dennis L.
Schlom Jeffrey
Bansal Geetha P.
The United States of America as represented by the Secretary of
Therion Biologics Corporation
LandOfFree
Generation of immune responses to prostate-specific antigen (PSA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Generation of immune responses to prostate-specific antigen (PSA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Generation of immune responses to prostate-specific antigen (PSA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-991666